GB201914860D0 - Inhibitor compounds - Google Patents

Inhibitor compounds

Info

Publication number
GB201914860D0
GB201914860D0 GB201914860A GB201914860A GB201914860D0 GB 201914860 D0 GB201914860 D0 GB 201914860D0 GB 201914860 A GB201914860 A GB 201914860A GB 201914860 A GB201914860 A GB 201914860A GB 201914860 D0 GB201914860 D0 GB 201914860D0
Authority
GB
United Kingdom
Prior art keywords
inhibitor compounds
inhibitor
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GB201914860A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Cancer Research Royal Cancer Hospital
Cancer Research Technology Ltd
Original Assignee
Institute of Cancer Research Royal Cancer Hospital
Cancer Research Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Cancer Research Royal Cancer Hospital, Cancer Research Technology Ltd filed Critical Institute of Cancer Research Royal Cancer Hospital
Priority to GB201914860A priority Critical patent/GB201914860D0/en
Publication of GB201914860D0 publication Critical patent/GB201914860D0/en
Priority to IL292182A priority patent/IL292182B1/en
Priority to US17/768,174 priority patent/US12528826B2/en
Priority to BR112022006953A priority patent/BR112022006953A2/pt
Priority to EP20793780.6A priority patent/EP4045510B1/en
Priority to KR1020227016037A priority patent/KR20220083761A/ko
Priority to PCT/GB2020/052588 priority patent/WO2021074620A1/en
Priority to CA3157716A priority patent/CA3157716A1/en
Priority to CN202080072281.5A priority patent/CN114650995A/zh
Priority to JP2022522065A priority patent/JP7668273B2/ja
Priority to AU2020365518A priority patent/AU2020365518B2/en
Priority to MX2022004419A priority patent/MX2022004419A/es
Priority to ES20793780T priority patent/ES3047908T3/es
Priority to ZA2022/03520A priority patent/ZA202203520B/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
GB201914860A 2019-10-14 2019-10-14 Inhibitor compounds Ceased GB201914860D0 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
GB201914860A GB201914860D0 (en) 2019-10-14 2019-10-14 Inhibitor compounds
IL292182A IL292182B1 (en) 2019-10-14 2020-10-13 History of [4,1]oxazepino[3,2-c]quinolinones as Bcl6 inhibitors
ES20793780T ES3047908T3 (en) 2019-10-14 2020-10-14 [1,4]oxazepino[2,3-c]quinolinone derivatives as blc6 inhibitors
PCT/GB2020/052588 WO2021074620A1 (en) 2019-10-14 2020-10-14 [1,4]oxazepino[2,3-c]qui noli none derivatives as blc6 inhibitors
BR112022006953A BR112022006953A2 (pt) 2019-10-14 2020-10-14 Composto ou um sal ou solvato, composição farmacêutica, e, método para o tratamento de câncer
EP20793780.6A EP4045510B1 (en) 2019-10-14 2020-10-14 [1,4]oxazepino[2,3-c]quinolinone derivatives as blc6 inhibitors
KR1020227016037A KR20220083761A (ko) 2019-10-14 2020-10-14 Bcl6 저해제로서의 [1,4]옥사제피노[2,3-c]퀴놀리논 유도체
US17/768,174 US12528826B2 (en) 2019-10-14 2020-10-14 [1,4]oxazepino[2,3-c]quinolinone derivatives as BCL6 inhibitors
CA3157716A CA3157716A1 (en) 2019-10-14 2020-10-14 [1,4]oxazepino[2,3-c]quinolinone derivatives as blc6 inhibitors
CN202080072281.5A CN114650995A (zh) 2019-10-14 2020-10-14 作为bcl6抑制剂的[1,4]氧杂氮杂䓬[2,3-c]喹啉酮衍生物
JP2022522065A JP7668273B2 (ja) 2019-10-14 2020-10-14 Ｂｃｌ６阻害剤としての［１，４］オキサゼピノ［２，３－ｃ］キノリノン誘導体
AU2020365518A AU2020365518B2 (en) 2019-10-14 2020-10-14 [1,4]oxazepino[2,3-c]quinolinone derivatives as BCL6 inhibitors
MX2022004419A MX2022004419A (es) 2019-10-14 2020-10-14 Derivados de [1,4]oxazepino[2,3c]quinolinona como inhibidores de bcl6.
ZA2022/03520A ZA202203520B (en) 2019-10-14 2022-03-25 [1,4]oxazepino[2,3-c]quinolinone derivatives as bcl6 inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201914860A GB201914860D0 (en) 2019-10-14 2019-10-14 Inhibitor compounds

Publications (1)

Publication Number Publication Date
GB201914860D0 true GB201914860D0 (en) 2019-11-27

Family

ID=68619494

Family Applications (1)

Application Number Title Priority Date Filing Date
GB201914860A Ceased GB201914860D0 (en) 2019-10-14 2019-10-14 Inhibitor compounds

Country Status (13)

Country Link
US (1) US12528826B2 (enExample)
EP (1) EP4045510B1 (enExample)
JP (1) JP7668273B2 (enExample)
KR (1) KR20220083761A (enExample)
CN (1) CN114650995A (enExample)
AU (1) AU2020365518B2 (enExample)
CA (1) CA3157716A1 (enExample)
ES (1) ES3047908T3 (enExample)
GB (1) GB201914860D0 (enExample)
IL (1) IL292182B1 (enExample)
MX (1) MX2022004419A (enExample)
WO (1) WO2021074620A1 (enExample)
ZA (1) ZA202203520B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3095371A1 (en) 2018-04-13 2019-10-17 Cancer Research Technology Limited Bcl6 inhibitors
GB201914860D0 (en) 2019-10-14 2019-11-27 Cancer Research Tech Ltd Inhibitor compounds
CA3154386A1 (en) 2019-10-17 2021-04-22 Michael Berlin Bifunctional molecules containing an e3 ubiquitine ligase binding moiety linked to a bcl6 targeting moiety
KR20230171979A (ko) 2021-04-16 2023-12-21 아비나스 오퍼레이션스, 인코포레이티드 Bcl6 단백질 분해의 조절제 및 관련 사용 방법
PE20250756A1 (es) 2022-06-06 2025-03-13 Treeline Biosciences Inc Degradadores bifuncionales de bcl6 de quinolona triciclica
EP4536649A1 (en) 2022-06-13 2025-04-16 Treeline Biosciences, Inc. Quinolone bcl6 bifunctional degraders
KR20250023481A (ko) 2022-06-13 2025-02-18 트리라인 바이오사이언시스, 인크. 1,8-나프티리딘-2-온 이종이작용성 bcl6 분해제
KR20240161027A (ko) * 2023-05-03 2024-11-12 인제대학교 산학협력단 BTK 분해제 및 Bcl-6 분해제를 포함하는 암의 예방 또는 치료용 약학적 조성물
AU2024331309A1 (en) * 2023-09-01 2026-03-19 Treeline Biosciences, Inc. Tricyclic quinolone bcl6 bifunctional degraders

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0259572A (ja) 1988-08-23 1990-02-28 Mitsubishi Kasei Corp ベンズイミダゾロン誘導体又はその塩類
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
DE69720965T2 (de) 1996-02-13 2004-02-05 Astrazeneca Ab Chinazolinderivate und deren verwendung als vegf hemmer
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
CA2349616A1 (en) 1998-12-04 2000-06-15 Neurosearch A/S New benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
PT1154774E (pt) 1999-02-10 2005-10-31 Astrazeneca Ab Derivados de quinazolina como inibidores de angiogenese
IL147309A0 (en) 1999-07-21 2002-08-14 Fujisawa Pharmaceutical Co Benzimidazolone derivatives and pharmaceutical compositions containg the same
AU2001258628A1 (en) 2000-05-31 2001-12-11 Astrazeneca Ab Indole derivatives with vascular damaging activity
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
WO2001094311A1 (en) 2000-06-08 2001-12-13 Mitsubishi Pharma Corporation Cytoprotectors
MXPA02012905A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como agentes de dano vascular..
MXPA02012903A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como inhibidores de angiogenesis.
UY27304A1 (es) 2001-05-24 2002-12-31 Avanir Pharmaceuticals Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación
WO2003095448A1 (en) 2002-05-06 2003-11-20 Bayer Pharmaceuticals Corporation Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
US7825132B2 (en) 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
US20050256157A1 (en) 2002-08-23 2005-11-17 Chiron Corporation Combination therapy with CHK1 inhibitors
WO2008011032A1 (en) 2006-07-17 2008-01-24 Amgen Inc. Quinazoline and pyridopyrimidine derivatives as p38 kinase inhibitors
WO2008066887A2 (en) 2006-11-30 2008-06-05 Albert Einstein College Of Medicine Of Yeshiva University Small molecule inhibitors of bcl6
US8686008B2 (en) 2007-08-16 2014-04-01 The University Of Mississippi Highly selective sigma receptor ligands
WO2009063240A1 (en) 2007-11-16 2009-05-22 Arrow Therapeutics Limited 2,4-diaminopyrimidine derivatives useful as inhibitors of aurora kinase
SG187502A1 (en) 2008-02-01 2013-02-28 Takeda Pharmaceutical Oxim derivatives as hsp90 inhibitors
AU2009314760B2 (en) 2008-11-11 2011-11-10 Je Il Pharmaceutical Co.,Ltd Novel tricyclic derivative or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition containing the same
BRPI1006942A2 (pt) 2009-01-23 2016-04-12 Rigel Pharmaceuticals Inc composto, composição farmacêutica, kit, métodos para inibir uma atividade de uma jak quinase, para tratar uma doença, para tratar a rejeição de transplante de aloenxerto em um receptor de transplante, para tratar uma reação de hipersensibilidade, e para inibir uma cascata de transdução de sinal, e, uso do composto
KR20120114355A (ko) 2010-01-13 2012-10-16 글락소스미스클라인 엘엘씨 화합물 및 방법
CA2840883C (en) 2011-07-07 2019-07-16 Merck Patent Gmbh Substituted azaheterocycles
CA2877146C (en) 2012-06-18 2020-10-20 Dart Neuroscience (Cayman) Ltd Substituted thiophene- and furan-fused azolopyrimidine-5-(6h)-one compounds
EP2964642B1 (en) 2013-03-05 2017-11-15 F. Hoffmann-La Roche AG Inhibitors of bruton's tyrosine kinase
US9943506B2 (en) 2013-06-17 2018-04-17 Cornell University BCL6 inhibitors as anticancer agents
CN105017159B (zh) 2014-04-28 2019-05-17 四川大学 5-氟-2,4-二取代氨基嘧啶衍生物及其制备方法和用途
US10266549B2 (en) 2014-08-25 2019-04-23 Salk Institute For Biological Studies ULK1 inhibitors and methods using same
US20160060260A1 (en) 2014-08-29 2016-03-03 Board Of Regents, The University Of Texas System Bromodomain inhibitors for treating disease
HK1244427A1 (zh) 2014-12-06 2018-08-10 Intra-Cellular Therapies, Inc. 有机化合物
WO2017007658A1 (en) 2015-07-07 2017-01-12 Rigel Pharmaceuticals, Inc. A combination for immune mediated cancer treatment
US11001570B2 (en) * 2016-12-13 2021-05-11 Boehringer Ingelheim International Gmbh 6-amino-quinolinone compounds and derivatives as BCL6 inhibitors
US11161839B2 (en) 2017-05-26 2021-11-02 The Institute Of Cancer Research: Royal Cancer Hospital 2-quinolone derived inhibitors of BCL6
JP7202315B2 (ja) 2017-05-26 2023-01-11 キャンサー・リサーチ・テクノロジー・リミテッド ベンズイミダゾロン由来のｂｃｌ６阻害剤
CA3095371A1 (en) 2018-04-13 2019-10-17 Cancer Research Technology Limited Bcl6 inhibitors
GB201819136D0 (en) 2018-11-23 2019-01-09 Cancer Research Tech Ltd Inhibitor compounds
GB201914860D0 (en) 2019-10-14 2019-11-27 Cancer Research Tech Ltd Inhibitor compounds

Also Published As

Publication number Publication date
AU2020365518B2 (en) 2026-04-23
JP2022551950A (ja) 2022-12-14
EP4045510A1 (en) 2022-08-24
IL292182A (en) 2022-06-01
KR20220083761A (ko) 2022-06-20
WO2021074620A1 (en) 2021-04-22
ZA202203520B (en) 2025-09-25
EP4045510C0 (en) 2025-07-30
WO2021074620A9 (en) 2021-06-17
MX2022004419A (es) 2022-08-08
US12528826B2 (en) 2026-01-20
CN114650995A (zh) 2022-06-21
AU2020365518A1 (en) 2022-04-14
ES3047908T3 (en) 2025-12-05
EP4045510B1 (en) 2025-07-30
IL292182B1 (en) 2026-02-01
US20240217987A1 (en) 2024-07-04
JP7668273B2 (ja) 2025-04-24
CA3157716A1 (en) 2021-04-22

Similar Documents

Publication Publication Date Title
IL289463A (en) Agonist-gipr compounds
GB201914860D0 (en) Inhibitor compounds
GB201905721D0 (en) Compounds
IL290087A (en) inhibitory substances
GB201819126D0 (en) Inhibitor compounds
GB202008201D0 (en) Inhibitor compounds
GB201905328D0 (en) Inhibitor compounds
GB202004960D0 (en) Inhibitor compounds
GB201910305D0 (en) Compounds
GB201908536D0 (en) Compounds
GB202110373D0 (en) Inhibitor compounds
GB201819136D0 (en) Inhibitor compounds
GB201910304D0 (en) Compounds
GB201908171D0 (en) Compounds
GB201908095D0 (en) Carboxy-MIDA-boronate compounds
GB201905318D0 (en) Inhibitor compounds
GB202117224D0 (en) Inhibitor compounds
GB202112240D0 (en) Inhibitor compounds
GB202107325D0 (en) Inhibitor compounds
GB202104781D0 (en) Inhibitor compounds
GB201806130D0 (en) Inhibitor compounds
GB201806131D0 (en) Inhibitor compounds
GB202016964D0 (en) Inhibitor compounds
GB202012969D0 (en) Inhibitor compounds
GB202008205D0 (en) Inhibitor compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)